Please login to the form below

Crucell

This page shows the latest Crucell news and features for those working in and with pharma, biotech and healthcare.

Janssen’s quest to prevent diseases taking hold

Janssen’s acquisition of Crucell in 2011 brought it a suite of promising platforms covering HIV, a universal flu vaccine, respiratory syncytial virus (RSV), which is an infection of the lungs

Latest news

Ebola vaccine halt 'a precaution' say researchers

Meanwhile, Johnson &Johnson (J&J) is also stepping up production of its own candidate - being developed by subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National
J&J to produce one million doses of Ebola vaccine

The vaccine is being developed by J&J's Netherlands-based subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National Institutes of Health (NIH). ... It combines Crucell's AdVac technology and Bavarian Nordi's MVA-BN
J&J fast-tracks Ebola vaccine

The US-based healthcare giant's subsidiary Crucell – based in the Netherlands – is collaborating with the Danish biotech Bavarian Nordic on a combination vaccine regimen with clinical trials in humans planned ... So far the regimen – which combines
Janssen boosts vaccines pipeline with GlycoVaxyn deal

Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead
J&J complete acquisition of Crucell

As a result of the deal, Crucell will become the centre for vaccines within the J&J group. ... In October 2010, J&J reached an agreement with Crucell on its 24.75 a share purchase offer.

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

Kiadis Pharma appoints new chief operations officer

Prior to his time at Janssen, Feijen held positions for the likes of Crucell, Avebe and Gist Brocades.
Cell Medica adds to senior management team

He brings extensive experience in biotechnology manufacturing to the role, having held senior leadership positions at Crucell, Merck, Roche and Schering-Plough.
TiGenix appoints Dr Marie Paule Richard

She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... pharmacovigilance and medical affairs at Crucell in Switzerland.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Medical Writer: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Associate Director: £75, 000-90, 000

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Global Business Development Director – Health Education: excellent commission

Senior Medical Writer: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Medical Education: Salary TBC

Account Manager / Account Director: Competative

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Manager / Senior Account Manager: 35, 000-40, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...